It remains to be seen whether the inhibition of CXCL10 production from epithelial cells could have a therapeutic potential in selected COVID-19 patients at increased risk of severe disease, by limiting the infiltration of CXCR3+ immune cells into lung tissue. The gene discussed is CXCL10; the disease is COVID-19.